vCaP ENZ was created through ADT and Enzalutamide to be used as a model for CRPC
| Inventor | Institute |
|---|---|
| Wytske van Weerden | Erasmus University Medical Centre |
| SKU: | 161960 |
|---|---|
| Product description: | CRPC VCaP cell lines (15 sublines made resistant to common antiandrogens through long-term passaging) – Enzalutamide A. VCaP Enzalutamide cells were generated by long-term culturing of VCaP cells in androgen depleted media with Enzalutamide, an AR antagonist. These cell lines can be used to study the role of AR signalling and mechanisms of resistance to androgen deprivation therapy and AR targeting agents in CRPC. This cell line is subclone A. |
| Receptors of note: | Androgen receptor |
| Parental cell line: | VCaP |
| Model description: | CRPC model |
| Disease: | Cancer |
| Cat. #: | 161960 |
|---|---|
| Cancer types: | Prostate cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Prostate |
| Model: | Tumour Cell Line |
| Primary citation: | Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769712 |
| Storage conditions: | liquid N2 |
|---|---|
| Shipping conditions: | Dry Ice |
| Growth medium: | RPMI1640 + 10% DCC-FCS + 1 uM ENZ |
| References: |
Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769723 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.